4156-75-6

Usage

Uses

Used in Pharmaceutical Industry:
LACTONE 5-HYDROXYMETHYL OROTIC ACID is used as an intermediate in the biosynthesis of pyrimidines for its role in the production of essential nucleotides, which are vital for DNA and RNA structure and function.
Used in the Synthesis of Nucleotides:
LACTONE 5-HYDROXYMETHYL OROTIC ACID is used as a precursor in the synthesis of uridine monophosphate (UMP) for its importance in nucleotide uridine production, which is crucial for protein and nucleic acid metabolism.
Used in Liver Disease Treatment:
LACTONE 5-HYDROXYMETHYL OROTIC ACID is used as a therapeutic agent for liver disease due to its demonstrated hepatoprotective and anti-fibrotic properties in animal models, indicating its potential in treating liver-related conditions.
Used in Medical Research and Development:
LACTONE 5-HYDROXYMETHYL OROTIC ACID is used as a target for further research and development in the field of medicine because of its unique chemical structure and biological activities, which could lead to new treatments and therapies.

InChI:InChI=1/C6H4N2O4/c9-4-2-1-12-5(10)3(2)7-6(11)8-4/h1H2,(H2,7,8,9,11)

Upstream product

• 6341-93-1 orotic acid 
• 50-00-0 formaldehyd 
• 65-86-1 2,4-dihydroxypyrimidine-6-carboxylic acid 
• 65-86-1 orotic acid 

Downstream Products

• 1079649-91-4 2,4-dihydroxy-6-isopropyl-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one 
• 1262443-60-6 1-(4-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-7-hydroxy-7-methyl-5,7-dihydrofuro[3,4-d]pyrimidin-2-yl)phenyl)-3-methylurea 
• 1262443-61-7 1-(4-(4'-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-5'H-spiro[cyclopropane-1,7'-furo[3,4-d]pyrimidine]-2'-yl)phenyl)-3-methylurea 
• 1079658-41-5 benzyl (2R)-1-[4-(4-acetylpiperazin-1-yl)-7-oxo-8-propan-2-yl-3,5,8-triazabicyclo[4.3.0]nona-1,3,5-trien-2-yl]pyrrolidine-2-carboxylate 
• 1079651-60-7 2-chloro-4-{[2-(4-chlorophenyl)-1,1-dimethylethyl]amino}-6-isopropyl-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one 
• 1079652-11-1 2-chloro-4-[2-(4-fluoro-phenyl)-1,1-dimethyl-ethylamino]-6-isopropyl-5,6-dihydro-pyrrolo[3,4-d]pyrimidin-7-one 
• 1079649-94-7 2,4-dichloro-6-isopropyl-5H-pyrrolo[3,4-d]pyrimidin-7(6H)-one 
• 1079655-16-5 4-(benzhydryl-amino)-2-[4-(2-dimethylamino-acetyl)-piperazin-1-yl]-6-isopropyl-5,6-dihydro-pyrrolo[3,4-d]pyrimidin-7-one 
• 1079655-01-8 2-{4-[4-(benzhydryl-amino)-6-isopropyl-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl]-piperazin-1-yl}-N,N-dimethyl-acetamide 
• 1079655-05-2 4-(benzhydryl-amino)-6-isopropyl-2-(4-methanesulfonyl-piperazin-1-yl)-5,6-dihydro-pyrrolo[3,4-d]pyrimidin-7-one 
• 1079654-72-0 2-(4-acetyl-piperazin-1-yl)-4-(benzhydryl-amino)-6-isopropyl-5,6-dihydro-pyrrolo[3,4-d]pyrimidin-7-one 
• 1079654-87-7 C₂₇H₃₂N₆O 
• 1079654-92-4 4-(benzhydryl-amino)-6-isopropyl-2-(2-methoxy-ethylamino)-5,6-dihydro-pyrrolo[3,4-d]pyrimidin-7-one 
• 1079655-11-0 N-{1-[4-(benzhydryl-amino)-6-isopropyl-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl]-pyrrolidin-3-yl}-acetamide 

Relevant academic research and scientific papers

Probing the Reactivity of 2,4-Dichlorofuro[3,4-d ]pyrimidin-7-one: A Versatile and Underexploited Scaffold to Generate Substituted or Fused Pyrimidine Derivatives

Herein, we describe the results of our investigation on the chemical reactivity and versatility of a poorly explored scaffold: 2,4-dichlorofuro[3,4-d ]pyrimidin-7-one (3). Highly functionalized pyrimidines can be obtained with a divergent approach by reacting the key intermediate 3 with different amine nucleophiles under carefully controlled reaction conditions. The set-up of a microwave-Assisted one-pot, two-or three-step protocol to rapidly generate 2,4,5,6-Tetrasubstituted or fused pyrimidines is also reported.

BICYCLIC PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT， AMELIORATION OR PREVENTION OF INFLUENZA

The present invention relates to a compound having the formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, codrug, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameloriating or preventing influenza.

Discovery of P2X3 selective antagonists for the treatment of chronic pain

Purinergic receptor P2X3 has been linked to analgesia in a number of pre-clinical models of pain, and is expressed in the human pain perception pathway. Only few P2X3-selective antagonists have been reported to date. This Letter describes the SAR and in vivo analgesic profile of a novel scaffold of selective P2X3 antagonists.

DIHYDROFUROPYRIMID1NE COMPOUNDS

The present invention provides mTOR inhibitors of the formula (I) wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods of making the compounds and intermediates thereof; and methods of using the compounds.

DIHYROFUROPYRMINDINE COMPOUNDS

The present invention provides mTOR inhibitors of the formula wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods of making the compounds and intermediates thereof; and methods of using the compounds.

OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE

Disclosed are compounds of Formula I, including steroisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e.g., mTOR).

PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS

Compounds of formula (I) or pharmaceutically acceptable salts thereof wherein R1, R2, R3, R4, and R5 and are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.